Literature DB >> 26369478

An update on myasthenia gravis, challenging disease for the dental profession.

Alessandro Tamburrini1, Federico Tacconi, Alberta Barlattani, Tommaso C Mineo.   

Abstract

Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating weakness and skeletal muscle fatigue. Clinical signs and symptoms may vary considerably according to the age at presentation, patterns of autoantibodies and associated thymic abnormalities, so that therapeutic options are highly individualized. Facial and oropharyngeal muscle weakness is common at disease onset, and therefore dentists are often the first health professionals to encounter these patients. Myasthenic patients require special consideration and advice in order to ensure optimal and safe dental treatment. Oral manifestations, treatment timing and modality, the choice and effects of drugs and medications, and prevention of myasthenic crisis are all important aspects with which dentists and oral health care providers should be thoroughly acquainted.

Entities:  

Mesh:

Year:  2015        PMID: 26369478     DOI: 10.2334/josnusd.57.161

Source DB:  PubMed          Journal:  J Oral Sci        ISSN: 1343-4934            Impact factor:   1.556


  3 in total

1.  Anesthetic considerations for a patient with myasthenia gravis undergoing deep sedation in an outpatient oral surgery setting.

Authors:  Shamit S Prabhu; Saad A Khan; Alexander L Doudnikoff; Uday N Reebye
Journal:  J Dent Anesth Pain Med       Date:  2019-02-28

2.  The Dental Management of Pediatric Patient Diagnosed with Myasthenia Gravis: A Case Report.

Authors:  Saad M AlManea; Mashael A AlHadlaq; Noura M AlBuqmi; Sultan S AlGomaiz
Journal:  Eur J Dent       Date:  2022-06-21

3.  Relationship between Oral Hypofunction and Sarcopenia in Community-Dwelling Older Adults: The Otassha Study.

Authors:  Yoshihiro Kugimiya; Masanori Iwasaki; Yuki Ohara; Keiko Motokawa; Ayako Edahiro; Maki Shirobe; Yutaka Watanabe; Shuichi Obuchi; Hisashi Kawai; Yoshinori Fujiwara; Kazushige Ihara; Hunkyung Kim; Takayuki Ueda; Hirohiko Hirano
Journal:  Int J Environ Res Public Health       Date:  2021-06-21       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.